Early Outcomes of Adult Heart Transplantation From COVID-19 Infected Donors.

Autor:	Madan S; Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: smadan@montefiore.org., Chan MAG; Department of Medicine, Montefiore Medical Center, Bronx, New York, USA., Saeed O; Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA., Hemmige V; Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Bronx, New York, USA., Sims DB; Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA., Forest SJ; Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA., Goldstein DJ; Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA., Patel SR; Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA., Jorde UP; Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA.
Jazyk:	angličtina
Zdroj:	Journal of the American College of Cardiology [J Am Coll Cardiol] 2023 Jun 20; Vol. 81 (24), pp. 2344-2357. Date of Electronic Publication: 2023 May 17.
DOI:	10.1016/j.jacc.2023.04.022
Abstrakt:	Background: There is a paucity of data on heart transplantation (HT) using COVID-19 donors. Objectives: This study investigated COVID-19 donor use, donor and recipient characteristics, and early post-HT outcomes. Methods: Between May 2020 and June 2022, study investigators identified 27,862 donors in the United Network for Organ Sharing, with 60,699 COVID-19 nucleic acid amplification testing (NAT) performed before procurement and with available organ disposition. Donors were considered "COVID-19 donors" if they were NAT positive at any time during terminal hospitalization. These donors were subclassified as "active COVID-19" (aCOV) donors if they were NAT positive within 2 days of organ procurement, or "recently resolved COVID-19" (rrCOV) donors if they were NAT positive initially but became NAT negative before procurement. Donors with NAT-positive status >2 days before procurement were considered aCOV unless there was evidence of a subsequent NAT-negative result ≥48 hours after the last NAT-positive result. HT outcomes were compared. Results: During the study period, 1,445 "COVID-19 donors" (COVID-19 NAT positive) were identified; 1,017 of these were aCOV, and 428 were rrCOV. Overall, 309 HTs used COVID-19 donors, and 239 adult HTs from COVID-19 donors (150 aCOV, 89 rrCOV) met study criteria. Compared with non-COV, COVID-19 donors used for adult HT were younger and mostly male (∼80%). Compared with HTs from non-COV donors, recipients of HTs from aCOV donors had increased mortality at 6 months (Cox HR: 1.74; 95% CI: 1.02-2.96; P = 0.043) and 1 year (Cox HR: 1.98; 95% CI: 1.22-3.22; P = 0.006). Recipients of HTs from rrCOV and non-COV donors had similar 6-month and 1-year mortality. Results were similar in propensity-matched cohorts. Conclusions: In this early analysis, although HTs from aCOV donors had increased mortality at 6 months and 1 year, HTs from rrCOV donors had survival similar to that seen in recipients of HTs from non-COV donors. Continued evaluation and a more nuanced approach to this donor pool are needed. Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu